Drug Development Updates

AstraZeneca and Eli Lilly have formed a strategic partnership to develop AZD3293, a promising oral BACE inhibitor for early Alzheimer's disease, with Lilly contributing $500 million in milestone payments.

Ascension Alexian Brothers Hospital Launches Novel Alzheimer's Treatment Trials, Including At-Home Injectable Option

3 months ago

Ascension Alexian Brothers hospital is conducting trials for remternetug, a new subcutaneous Alzheimer's treatment derived from donanemab that patients can self-administer at home.

WashU Medicine Launches Groundbreaking Trial of Remternetug to Prevent Early-Onset Alzheimer's

3 months ago

Washington University School of Medicine initiates a pioneering trial of remternetug, a monoclonal antibody designed to prevent Alzheimer's disease by targeting amyloid-beta before symptom onset.

Lecanemab Demonstrates Sustained Clinical Benefit in Early Alzheimer's Disease

2 years ago

Lecanemab significantly reduces brain amyloid levels and slows cognitive decline in early Alzheimer's disease patients during the core treatment phase.

Blood-Brain Barrier Breakthrough: Novel Delivery System Shows Promise for Brain Disease Treatment

5 years ago

A new molecular Trojan horse delivery system successfully transports therapeutic proteins and genes across the blood-brain barrier, potentially revolutionizing treatment for neurological diseases.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy